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BACKGROUND
With the vision of “a world free of schistosomiasis,” the World Health Organization 
(WHO) set ambitious goals of control of this debilitating disease and its elimination 
as a public health problem by 2020 and 2025, respectively. As these milestones become 
imminent, and if programs are to succeed, it is important to evaluate the WHO pro-
grammatic guidelines empirically.
METHODS
We collated and analyzed multiyear cross-sectional data from nine national schistoso-
miasis control programs (in eight countries in sub-Saharan Africa and in Yemen). Data 
were analyzed according to schistosome species (Schistosoma mansoni or S. haematobium), 
number of treatment rounds, overall prevalence, and prevalence of heavy-intensity 
infection. Disease control was defined as a prevalence of heavy-intensity infection of 
less than 5% aggregated across sentinel sites, and the elimination target was defined 
as a prevalence of heavy-intensity infection of less than 1% in all sentinel sites. Heavy-
intensity infection was defined as at least 400 eggs per gram of feces for S. mansoni 
infection or as more than 50 eggs per 10 ml of urine for S. haematobium infection.
RESULTS
All but one country program (Niger) reached the disease-control target by two treat-
ment rounds or less, which is earlier than projected by current WHO guidelines (5 to 
10 years). Programs in areas with low endemicity levels at baseline were more likely 
to reach both the control and elimination targets than were programs in areas with 
moderate and high endemicity levels at baseline, although the elimination target was 
reached only for S. mansoni infection (in Burkina Faso, Burundi, and Rwanda within 
three treatment rounds). Intracountry variation was evident in the relationships be-
tween overall prevalence and heavy-intensity infection (stratified according to treat-
ment rounds), a finding that highlights the challenges of using one metric to define 
control or elimination across all epidemiologic settings.
CONCLUSIONS
These data suggest the need to reevaluate progress and treatment strategies in na-
tional schistosomiasis control programs more frequently, with local epidemiologic 
data taken into consideration, in order to determine the treatment effect and appropri-
ate resource allocations and move closer to achieving the global goals. (Funded by the 
Children’s Investment Fund Foundation and others.)
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Schistosomiasis is a parasitic neglect-ed tropical disease that is estimated to currently infect more than 140 million 
persons.1,2 Ninety percent of the disease burden 
is in sub-Saharan Africa, where the main species 
that cause schistosomiasis in humans are Schis-
tosoma mansoni (intestinal schistosomiasis) and 
S. haematobium (urogenital schistosomiasis), which 
are transmitted through feces and urine, respec-
tively.3,4 Symptoms of schistosomiasis include 
anemia, stunting, fever, genital lesions, and ir-
reversible organ damage.5-7 Preventive chemo-
therapy with praziquantel is the strategy recom-
mended by the World Health Organization 
(WHO) for the control of schistosomiasis; this 
therapy is distributed primarily to school-age 
children 5 to 15 years of age, who have the high-
est infection burden and who can be reached 
efficiently through schools.8 The preventive che-
motherapy strategy is determined according to 
the prevalence of the infection (estimated by 
initial parasitologic assessment) at the imple-
mentation unit level (usually the district). A 
prevalence of infection below 10% entails the 
administration of preventive chemotherapy every 
3 years; 10 to 49%, treatment every 2 years; and 
50% or greater, treatment annually.9
The initial success of disease control in some 
countries10 has led to the more ambitious WHO 
vision of “a world free of schistosomiasis.”11 The 
WHO thus set goals for controlling schistoso-
miasis morbidity (referred to here as disease 
control; defined as a prevalence of heavy-inten-
sity infection of <5% aggregated across sentinel 
sites) by 2020 and achieving the elimination of 
schistosomiasis as a public health problem (re-
ferred to here as elimination; defined as a preva-
lence of heavy-intensity infection of <1% in all 
sentinel sites) by 2025 in all countries where 
schistosomiasis is endemic. The complete inter-
ruption of transmission is also a target in selected 
regions by 2025 (Fig. 1).11-13 The WHO strategic 
plan provides guidance on how programs can 
progress from control of schistosomiasis to 
elimination and interruption of transmission.11
One may predict that the timelines for tran-
sitioning between goals will not be uniform 
across all countries, owing to their epidemio-
logic and endemicity heterogeneities (Fig. 1). 
Hence, there exists a need to analyze quantita-
Figure 1. Schematic Representation of Program Progression toward Elimination of Schistosomiasis and Proposed 
Timelines from the World Health Organization (WHO).
Recommended WHO strategies include the control of the disease by means of preventive chemotherapy, with the 
use of complementary interventions where possible, and the elimination of the disease as a public health problem 
by means of adjusted preventive chemotherapy, with the use of complementary interventions being strongly recom-
mended. The elimination of transmission by means of intensified preventive chemotherapy in residual areas of 
transmission and complementary interventions is considered to be essential.11
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tive data, captured by means of program moni-
toring, in order to validate and update these 
guidelines. Recent theoretical modeling projects 
that the 2020 goal of disease control inherent in 
the current treatment guideline is probably ob-
tainable in areas in which prevalence is low or 
moderate but that the goal will be missed in 
areas in which prevalence is high.14
We aimed to elucidate empirically whether 
countries have already reached the 2020 and 
2025 goals, to investigate how many treatment 
rounds were necessary to reach these targets (if 
met), and to assess whether a one-size-fits-all 
approach would be appropriate for guiding 
schistosomiasis treatment strategies to reach the 
WHO-defined threshold criteria for disease con-
trol and elimination. Nationally representative 
cross-sectional epidemiologic data regarding both 
S. mansoni and S. haematobium were made avail-
able by the national ministries of health in nine 
countries where schistosomiasis is endemic.
 Me thods
 Data Collation
Parasitologic data (parasite egg counts from 
stool and urine samples) were collated from the 
Schistosomiasis Control Initiative–supported 
multiyear, cross-sectional sentinel-site surveys 
in nine countries, which assessed the reduction 
in prevalence and intensity of schistosomiasis 
among school-age children after treatment. The 
inclusion criteria were the following: countries 
in which ministries of health were supported by 
the Schistosomiasis Control Initiative; status of 
having more than 2 years of sentinel-site survey 
data after baseline; and cross-sectional data for 
school-age children 5 to 15 years of age. The 
countries that were included and information 
about the programs are shown in Figure 2 and 
in Table S1 in the Supplementary Appendix, 
available with the full text of this article at 
NEJM.org.
Figure 2. Countries from Which Data Were Analyzed.
The map on the left shows the locations of countries within Africa as well as the location of Yemen. Dots on the maps on the right indi-
cate the areas from which the selected sentinel sites were chosen according to the inclusion criteria. From left to right, starting in the 
top left square, the total numbers of sentinel sites were as follows: 21 in Mali, 8 in Niger, 36 in Yemen, 16 in Burkina Faso, 6 in Rwanda, 
39 in Uganda, 31 in Burundi, 21 in Tanzania, and 22 in Malawi. Burundi and Mali were split into two segments in this study; in Burundi, 
surveys began in different years in the pilot program and national program, and in Mali, different treatment strategies were implemented 
in the Segou region and the Bamako and Koulikoro regions.
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Burundi Tanzania Malawi
Niger
Rwanda Uganda
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Surveys took place approximately 6 weeks 
before the next treatment round (i.e., just under 
1 year after the last treatment round for annual 
preventive chemotherapy programs and just un-
der 2 years after the last treatment round for 
programs with preventive chemotherapy admin-
istered every 2 years). The first year of treatment 
(baseline treatment) varied — ranging from 
2003 to 2012 — among countries where treat-
ment was provided depending on schistosomia-
sis prevalence levels.
The data used in this study were collected as 
part of the monitoring and evaluation activities 
of the schistosomiasis control programs taking 
place in these countries where the disease is 
endemic. Ethics approval was granted by the St. 
Mary’s Hospital Local Ethics Research Commit-
tee, research and development office (part of the 
Imperial College Research Ethics Committee), as 
a constituent part of the ongoing Schistosomia-
sis Control Initiative activities, and by the min-
istry of health ethical review boards in these 
countries.
Statistical Analysis
Sample-size calculations for each country pro-
gram followed standardized procedures used at 
the Schistosomiasis Control Initiative that have 
been described in detail elsewhere (references 
shown in Table S1). These procedures provided 
information about the number of sentinel sites 
(schools) and children to be sampled within 
each site, and the analysis was powered to detect 
a preset difference in prevalence at a given ad-
ministrative level for the country, with account-
ing for clustering (a design effect) at the sentinel-
site level. Survey methods were standardized 
across countries.
Standard Kato–Katz and urine filtration meth-
ods were used to detect S. mansoni and S. haema-
tobium infection, respectively. The infection inten-
sity category with a 95% confidence interval was 
calculated according to treatment round, schisto-
some species, and country program.9 For S. man-
soni infection, the infection intensity — the pro-
portion of persons with a given number of 
schistosome eggs per gram of feces — was de-
fined as follows: light intensity, 1 to 99 eggs 
per gram; moderate intensity, 100 to 399 eggs per 
gram; and heavy intensity, at least 400 eggs 
per gram. For S. haematobium infection, the infec-
tion intensity — the proportion of persons with 
a given number of eggs per 10 ml of urine — 
was defined as follows: light intensity, 1 to 50 
eggs per 10 ml; and heavy intensity, more than 
50 eggs per 10 ml.
The mean prevalence and 95% confidence in-
tervals were calculated to account for the cluster-
ing of data at the sentinel-site level, with the use 
of the R survey package.15 The point (mean) preva-
lence estimates were used for the comparison 
with WHO guidelines, since the guidelines do 
not require calculations of 95% confidence inter-
vals. We assessed whether the mean prevalence 
of heavy-intensity infection across sentinel sites 
decreased to less than 5%, which would be in-
dicative of disease control, and decreased to less 
than 1% in all sentinel sites, which would be 
indicative of elimination.11 The overall prevalence 
and the prevalence of moderate-intensity plus 
heavy-intensity infection (S. mansoni only) were 
also estimated and compared with trends of heavy-
intensity infection prevalence. Although the WHO 
guidelines use the prevalence of heavy-intensity 
infection as an indirect measure of morbidity (as-
suming that morbidity is proportional to infec-
tion intensity), we included the combined measure 
Figure 3 (facing page). Changes in Prevalence  
of Schistosoma mansoni Infection over Time  
among School-Age Children.
Shown are the temporal changes in the prevalence  
of S. mansoni infection among school-age children 
 according to sentinel site for each country (light blue 
lines) and aggregated (mean value) across sentinel 
sites from each country (colored lines); the number  
of sentinel sites is shown for each country or its pro-
grams. Dashed lines show the 5% prevalence cutoff  
for heavy-intensity infection, indicating disease control; 
dotted lines show the 1% prevalence cutoff for heavy-
intensity infection, indicating the elimination of schisto-
somiasis as a public health problem. The aggregated 
mean line must be under the 5% cutoff to show disease 
control; all the lines (each representing a sentinel site) 
must be under the 1% cutoff to indicate elimination. 
Columns represent the overall prevalence, the preva-
lence of moderate-intensity plus heavy-intensity infec-
tion, and the prevalence of heavy-intensity infection. 
The I bars indicate 95% confidence intervals that were 
calculated by accounting for clustering of the data ac-
cording to sentinel site. The y axes are not proportional; 
the axis area of lower prevalence is expanded to show 
detail. In Burundi, data were available from 12 sentinel 
sites for the pilot program and from 19 sentinel sites 
for the national program; in Mali, data were available 
from 10 sentinel-site schools in the Segou region and 
from 11 sentinel-site schools in the Bamako and Kouli-
koro regions (combined).
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of the prevalence of moderate-intensity plus heavy-
intensity infection because of uncertainty in the 
appropriateness of egg-count thresholds for in-
tensity and because some degree of morbidity is 
believed to be caused by lighter infections.16
R esult s
Baseline Results
Endemicity at baseline varied according to schis-
tosome species and country. The prevalence of 
Figure 4. Changes in Prevalence of S. haematobium Infection over Time among School-Age Children.
Shown are the temporal changes in the prevalence of S. haematobium infection among school-age children accord-
ing to sentinel site for each country (light blue lines) and aggregated (mean value) across the sentinel sites from 
each country (colored lines); the number of sentinel sites is shown for each country or its programs. Dashed lines 
show the 5% prevalence cutoff for heavy-intensity infection, indicating disease control; dotted lines show the 1% 
prevalence cutoff for heavy-intensity infection, indicating the elimination of schistosomiasis as a public health prob-
lem. Columns represent the overall prevalence and the prevalence of heavy-intensity infection. The I bars indicate 
95% confidence intervals that were calculated by accounting for clustering of the data according to sentinel site.  
The y axes are not proportional; the axis area of lower prevalence is expanded to show detail.
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S. mansoni ranged from 1.9% (95% confidence 
interval [CI], 0.5 to 6.9) in Malawi to 45.4% (95% 
CI, 35.6 to 55.7) in Uganda. The prevalence of 
S. haematobium ranged from 9.8% (95% CI, 6.0 to 
15.5) in Malawi to 82.1% (95% CI, 70.1 to 90.0) 
in the Segou region of Mali.9 Despite this hetero-
geneity, the infection intensity in all countries 
decreased after the first round of treatment to 
below or within 0.8 percentage points of the 5% 
prevalence for the heavy-intensity threshold for 
control of S. mansoni infection and within 3.3 per-
centage points for S. haematobium infection (Figs. 
3 and 4 and Figs. S1 and S2).
Treatment reduced the prevalence of heavy-
intensity infection by both species to below 5% 
in all countries except Niger (5.4%; 95% CI, 2.0 to 
13.8), which only marginally missed the metric 
for S. haematobium infection in the first treatment 
round (Figs. 3 and 4 and Table 1). The more 
ambitious target of elimination of schistosomia-
sis as a public health problem was achieved only 
for S. mansoni infection and only in half the 
country programs. Moreover, Malawi had already 
reached the elimination target for S. mansoni in-
fection at baseline.
S. mansoni Infection
All 10 country programs reached the disease-
control target (prevalence of heavy-intensity in-
fection of <5%) after two rounds of treatment or 
fewer (Fig. 3 and Table 1 and Fig. S1). This in-
cluded Uganda, which had a relatively high preva-
lence at baseline. However, a subsequent gradual 
increase in the prevalence of heavy-intensity infec-
tion to just over the 5% threshold was observed 
in Uganda after the third and fourth treatment 
rounds. Burkina Faso, Burundi (pilot and national 
programs), Malawi, and Rwanda reached the 
elimination target after three rounds of treatment 
or fewer (but these sites had a baseline mean 
prevalence of heavy-infection intensity that was 
already below the 5% disease-control threshold).
According to the more conservative criteria of 
an overall prevalence of moderate-intensity plus 
heavy-intensity infection of less than 5% to rep-
resent disease control and of less than 1% to 
represent elimination (S. mansoni infection only), 
6 country programs were already below the 
threshold of less than 5% prevalence at baseline, 
and 1 country program (in the Segou region of 
Mali) met this target after one round of treat-
ment (Fig. 3 and Table 1). Three country pro-
grams (Burkina Faso, Malawi, and Rwanda) 
achieved elimination, and according to the cur-
rently available data, 3 of the 10 country pro-
grams did not reach any target (disease control 
or elimination) in the relatively short treatment 
period that included the data currently available.
S. haematobium Infection
All the countries except Malawi and Yemen had 
a baseline prevalence of heavy-intensity S. haema-
tobium infection of more than 5%. By the second 
treatment round, all the countries except Niger 
were below this threshold, thus meeting the 
disease-control criteria (Fig. 4 and Table 1 and 
Fig. S2). The prevalence of heavy-intensity infec-
tion in Niger decreased from 20.8% (95% CI, 
12.1 to 33.5) at baseline to 5.4% (95% CI. 2.0 to 
13.8) after a single treatment round, just missing 
the disease-control target.
Although three country programs reached a 
prevalence of less than 1% for heavy-intensity in-
fection aggregated across sentinel sites (Fig. 4), 
no countries reached this threshold in every 
sentinel site with regard to S. haematobium infec-
tion. Thus, the elimination goal was not met.
Discussion
The WHO provides guidance on the expected 
number of years of treatment to reach schisto-
somiasis control and the elimination of schis-
tosomiasis as a public health problem (5 to 10 
years for control, plus an additional 3 to 6 years 
for elimination). These data show that these 
thresholds are often reached sooner, whether 
treatment occurs annually or every 2 years. With 
the exception of S. haematobium infection in Niger, 
all the programs reached the disease-control 
target in two or fewer treatment rounds (i.e., 
between 1 and 2 years, depending on treatment 
frequency). However, six country programs start-
ed with a prevalence of heavy-intensity infection 
of less than 5% for S. mansoni infection, which 
indicated that they were already within the dis-
ease-control target at baseline. With regard to 
S. mansoni infection, the goal of elimination of 
schistosomiasis as a public health problem was 
reached by five programs with the use of three 
or fewer treatment rounds. This prompts the 
question as to what strategy to adopt in cases in 
which the baseline prevalence of heavy-intensity 
infection already meets the threshold target. The 
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areas where S. haematobium was endemic had 
higher overall infection levels at baseline than 
S. mansoni areas, and none reached the elimina-
tion goals within the time frame of this study. 
Countries where the prevalence is endemically 
low, which also had a lower prevalence of heavy-
intensity infection at baseline (≤1.5% for S. man-
soni infection), reached the elimination target 
sooner than was proposed by the guidelines. 
Our results, which are based on analysis of na-
tionally representative data sets from multiple 
countries, complement the theoretical modeling 
that projects that achievement of disease control 
is possible in areas with low or moderate preva-
lence and that elimination is possible in areas 
with low prevalence.14 We believe that this com-
bination of programmatic data and mathemati-
cal models could inform programmatic goals 
and targets.
The case of Uganda, however, shows that 
goals may be reached but are reversible. Reasons 
behind this rebound may reflect factors related 
in part to the influx of refugees, reduced adher-
ence to treatment, or changes in drug efficacy.17 
Such rebounds are nevertheless particularly rel-
evant wherever program stability is impeded, ow-
ing to, for example, civil unrest (as in Burundi) 
or war (as in Yemen). We also highlight variation 
among sentinel sites within each country (Figs. 
3 and 4); this factor requires consideration when 
the country-level disease-control targets pro-
posed by the WHO are reviewed. In addition, the 
effectiveness of program implementation may 
vary over time. Thus, it is important to define 
time periods over which control and elimination 
targets should be sustained in order for success 
to be declared, and it is also important to be 
vigilant to recrudescence wherever interruption 
of transmission has not been achieved.
As expected, we observed a strong positive 
association between overall infection prevalence 
and either the prevalence of heavy-intensity in-
fection or the prevalence of moderate-intensity 
plus heavy-intensity infection (Fig. S3). There was 
substantial variation of data points among coun-
tries and treatment rounds, which was probably 
caused by the heterogeneity of underlying adult 
parasite loads (which was perhaps due to varia-
tion in exposure among human hosts) such that 
the intensity of infection and subsequent disease-
related sequelae vary substantially among areas 
with a similar prevalence of infection. The mag-
nitude of the change in the prevalence of infec-
tion after treatment varied substantially among 
country programs. This finding emphasizes the 
need for research on appropriate morbidity indi-
cators.
Heavy-intensity infections are not the only 
type of infections that lead to schistosomiasis-
related complications16; therefore, moderate-inten-
sity plus heavy-intensity infections were com-
bined to form an additional metric of morbidity. 
In considering the aims of disease control and 
elimination, since control thresholds may be 
reached relatively quickly, it would be worth 
considering this metric in order to adequately 
accommodate the larger population group that 
may have schistosomiasis-related complications.
An important limitation of this study is the 
absence of available data on specific treatment 
coverage, which can vary substantially among 
national-scale preventive chemotherapy programs 
(see the Supplementary Appendix). Other infor-
mation, such as migration patterns and school 
enrollment and attendance rates, may also influ-
ence the effectiveness of preventive chemother-
apy programs and explain variation among study 
areas. Detailed information on these factors has 
not been routinely collected. This situation is 
common in programs regarding neglected trop-
ical diseases, and we recommend that such 
supplementary operational data collection be in-
tegrated into all routine monitoring and evalua-
tion data-collection protocols.
Furthermore, our data serve to highlight sev-
eral additional key issues that could be clarified 
in future WHO guidelines. For instance, more 
than half the programs in our study involved 
sentinel sites with mixed S. mansoni and S. haema-
tobium infections. Although we, following the 
standard WHO guidelines and monitoring and 
evaluation guidelines, analyzed intestinal and 
urogenital schistosomiasis independently, it ap-
pears to be intuitive that some areas may have 
had higher levels of infection prevalence when 
both species were combined or when underlying 
interactions occurred, which thereby influenced 
their threshold targets.18 Similarly, adults and 
preschool-age children are, in general, absent 
from routine monitoring and evaluation, so data 
from school-age children alone are used as a 
proxy for the situation in the wider community. 
It appears to be unrealistic to determine wheth-
er the targets of disease control, elimination of 
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schistosomiasis as a public health problem, and 
in particular interruption of transmission have 
been met without the consideration of this un-
monitored reservoir. This issue becomes even 
more apparent when one considers the concur-
rent role of potential zoonotic reservoirs of 
schistosomiasis within regions where the dis-
ease is endemic, particularly in those areas that 
are considered to have persistent hot spots.10
Finally, what has not yet been adequately ad-
dressed is whether there will still be true disease 
in the community even after the targets have been 
reached, since schistosomiasis-related complica-
tions (e.g., genital schistosomiasis and hepato-
splenomegaly) can continue many years after the 
infection has ceased. True disease control and 
elimination of the disease as a public health 
problem require the redefining of disease (mor-
bidity) control (not to be completely dependent 
on egg output), improved diagnostic tools, and 
the incorporation of new strategies to address 
long-term complications.
In countries where the prevalence of heavy-
intensity infection is less than 5% at baseline, it 
is unclear whether they should aim immediately 
for elimination or continue to treat according to 
guidelines for 5 to 10 years. The key messages 
of our study are that countries often achieve 
disease control after very few treatment rounds 
and that the universal timeline currently recom-
mended is not appropriate for all programs and 
will be affected by baseline endemicity, schisto-
some species, and the context-specific relation-
ship between infection and morbidity, among 
other extraneous factors.
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